Scynexis Stock Price, News & Analysis

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company focused on developing medicines to help patients overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. According to the company’s disclosures, SCYNEXIS is developing a proprietary antifungal platform known as “fungerps”, a novel class of triterpenoid antifungals that act as structurally distinct glucan synthase inhibitors. These agents are being advanced to address systemic fungal diseases and other serious fungal infections where existing therapies have important limitations.

Core focus and antifungal platform

SCYNEXIS describes triterpenoid antifungals, or fungerps, as a new class of glucan synthase inhibitors with the potential for both oral and intravenous (IV) formulations. Company materials state that this class has demonstrated broad-spectrum antifungal activity in vitro and in vivo, including against multidrug-resistant pathogens and strains resistant to azoles and echinocandins. The platform is intended to address infections caused by organisms such as Candida and Aspergillus species, including drug-resistant strains, as well as other fungal genera referenced in earlier descriptions.

The first representative of this class is ibrexafungerp, which has been licensed to GSK under an exclusive license agreement. SCYNEXIS reports that the U.S. Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients has also been described in company communications.

Relationship with GSK and BREXAFEMME

Under the exclusive license agreement with GSK, SCYNEXIS granted GSK an exclusive, royalty-bearing, sublicensable license for the development, manufacture, and commercialization of ibrexafungerp, including BREXAFEMME, for all indications in specified territories outside Greater China and certain other countries already licensed to third parties. An 8-K filing dated October 14, 2025, explains that this agreement is supported by a Transitional Manufacturing and Supply Agreement and that the parties have amended aspects of the collaboration through binding memoranda of understanding.

SCYNEXIS has disclosed that it is progressing the transfer of the BREXAFEMME New Drug Application (NDA) to GSK. Company press releases state that, following relaunch of BREXAFEMME by GSK for VVC and refractory VVC in the U.S. market, SCYNEXIS may receive net sales milestones and royalties, net of payments to Merck, in specified ranges. The company also notes that the triterpenoid antifungal class, represented by ibrexafungerp, is the first new antifungal class approved since 2001.

Pipeline: SCY-247 and next-generation fungerps

Beyond ibrexafungerp, SCYNEXIS is advancing additional antifungal assets from the fungerp class that are in clinical, pre-clinical, and discovery phases. A key focus is SCY-247, described by the company as a second-generation triterpenoid antifungal and next-generation fungerp. SCY-247 is under development for the treatment and prevention of invasive fungal infections, with the potential to provide therapeutic advantages in both oral and IV formulations.

SCYNEXIS has reported positive results from a Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) study of oral SCY-247 in healthy participants. According to company disclosures, SCY-247 was generally well tolerated across evaluated cohorts, with no serious or severe treatment-emergent adverse events or dose-limiting toxicities observed. The pharmacokinetic profile showed dose-proportional behavior, rapid absorption, and achievement of target exposures at doses lower than the first-generation fungerp, which the company notes may translate into a tolerability advantage. These data support continued clinical development, including plans for further Phase 1 work with an IV formulation and a Phase 2 study in invasive candidiasis.

In addition to clinical work, SCYNEXIS has highlighted multiple preclinical and translational studies of SCY-247. Presentations referenced by the company describe in vitro activity against Candida auris, including isolates with mutations associated with echinocandin resistance, uniform activity against various Candida species with no indication of cross-resistance to echinocandins, and in vivo efficacy in murine models of invasive candidiasis. Other data sets focus on activity against echinocandin-resistant Candida glabrata, cryptic Aspergillus species, and Lomentospora prolificans, illustrating the broad-spectrum antifungal profile the company associates with SCY-247.

Clinical and regulatory activities

SCYNEXIS has described a Phase 3 trial known as the MARIO study, which was designed to evaluate oral ibrexafungerp as a potential step-down therapy following IV echinocandin treatment for invasive candidiasis. Company communications explain that the study was placed on clinical hold by the FDA due to manufacturing-related concerns and later resumed after new clinical supplies were manufactured at another site and the hold was lifted. Subsequent disclosures and an 8-K filing state that SCYNEXIS and GSK entered into a binding memorandum of understanding resolving a disagreement related to the MARIO study, under which SCYNEXIS agreed to wind down and terminate the study in exchange for specified payments from GSK. The company has stated that it will not receive additional milestone payments from GSK specifically associated with the MARIO study but that other potential milestones and royalties under the broader license agreement remain unchanged.

In parallel, SCYNEXIS has emphasized ongoing collaboration with academic and clinical partners. For example, the company has reported that a series of antifungal compounds from its triterpenoid platform are included among projects funded by a federal grant to an accelerator consortium led by researchers from the Hackensack Meridian Center for Discovery and Innovation and the Johns Hopkins Bloomberg School of Public Health. This collaboration aims to progress next-generation fungerp candidates from early preclinical stages to investigational new drug (IND)-ready status.

Stock listing and Nasdaq compliance

SCYNEXIS’s common stock trades on Nasdaq under the ticker symbol SCYX. In June 2025, the company received a notice from Nasdaq indicating that its closing bid price had been below the $1.00 per share minimum required for continued listing on the Nasdaq Global Market for 30 consecutive business days, triggering a standard 180-day compliance period. SCYNEXIS disclosed that it could seek an additional compliance period by transferring to the Nasdaq Capital Market if certain conditions are met. In a later press release, the company reported that Nasdaq granted an additional 180-day extension to regain compliance with the minimum bid price requirement, and that SCYNEXIS continues to meet other continued listing criteria for the Nasdaq Capital Market. The company has indicated it may consider actions such as a reverse stock split to cure any remaining deficiency.

Business model and revenue sources

Based on its public statements, SCYNEXIS is a development-stage biotechnology company whose activities center on research, clinical development, and partnering around its antifungal assets. The company’s reported revenues in recent periods primarily consist of license agreement revenue associated with the GSK license agreement for ibrexafungerp. SCYNEXIS also references the potential for future net sales milestones and royalties from GSK following the relaunch and commercialization of BREXAFEMME for approved indications. In addition, SCYNEXIS has discussed exploring non-dilutive funding opportunities, including federal grants and collaborations, to support the development of SCY-247 and other next-generation fungerps.

Governance and shareholder matters

SCYNEXIS files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. An 8-K filed on July 1, 2025, summarizes the results of the company’s 2025 Annual Meeting of Stockholders, including the re-election of directors, ratification of the independent registered public accounting firm, and advisory approval of executive compensation as described in the proxy statement. These filings provide additional detail on risk factors, governance practices, and financial condition.

Risk considerations

SCYNEXIS notes in its press releases that statements about future events, such as clinical development plans, potential advantages of SCY-247, expected cash runway, and anticipated milestone or royalty payments, are forward-looking and subject to risks and uncertainties. The company directs readers to the risk factors section of its most recent Form 10-K and other SEC filings for a more complete discussion of these risks. As with many biotechnology companies focused on drug development, SCYNEXIS highlights regulatory, clinical, and commercial uncertainties that could affect outcomes.

Summary

In summary, SCYNEXIS, Inc. is a Nasdaq-listed biotechnology company concentrating on antifungal drug development through its proprietary fungerp platform. Its first-generation agent, ibrexafungerp, is FDA-approved as BREXAFEMME for specific vulvovaginal candidiasis indications and is licensed to GSK for broader development and commercialization. The company is advancing second-generation assets such as SCY-247 through clinical and preclinical programs, while also managing its collaboration with GSK, academic partnerships, and Nasdaq listing requirements. Investors and other stakeholders can review SCYNEXIS’s SEC filings and company announcements for detailed, up-to-date information on its programs, financials, and regulatory status.